Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12860987
Saito S, et al. (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278, 37536-44 12860987
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S6-p - p53 (human)
Modsite: __MEEPQsDPsVEPP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S6‑p, p53 iso2 (human): S6‑p, p53 iso4 (human): , p53 (mouse): S9‑p, p53 iso2 (mouse): S9‑p, p53 (rat): S6‑p, p53 (rabbit): S6‑p, p53 (green monkey): S6‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase
Downstream Regulation
Effect of modification (function):  acetylation, phosphorylation
Comments:  acetylation of p53 sites, necessary for phosphorylation of other p53 sites

S9-p - p53 (human)
Modsite: EEPQsDPsVEPPLsQ SwissProt Entrez-Gene
Orthologous residues
p53 (human): S9‑p, p53 iso2 (human): S9‑p, p53 iso4 (human): , p53 (mouse): S12‑p, p53 iso2 (mouse): S12‑p, p53 (rat): S9‑p, p53 (rabbit): S9‑p, p53 (green monkey): S9‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase
Downstream Regulation
Effect of modification (function):  acetylation, phosphorylation
Comments:  acetylation of p53 sites, necessary for phosphorylation of other p53 sites

S15-p - p53 (human)
Modsite: PsVEPPLsQEtFsDL SwissProt Entrez-Gene
Orthologous residues
p53 (human): S15‑p, p53 iso2 (human): S15‑p, p53 iso4 (human): , p53 (mouse): S18‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (green monkey): S15‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase
Downstream Regulation
Effect of modification (function):  acetylation, phosphorylation
Comments:  acetylation of p53 sites, necessary for phosphorylation of other p53 sites

T18-p - p53 (human)
Modsite: EPPLsQEtFsDLWkL SwissProt Entrez-Gene
Orthologous residues
p53 (human): T18‑p, p53 iso2 (human): T18‑p, p53 iso4 (human): , p53 (mouse): T21‑p, p53 iso2 (mouse): T21‑p, p53 (rat): T18‑p, p53 (rabbit): T18‑p, p53 (green monkey): T18‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
PALA no change compared to control
taxol no change compared to control
nocodazole no change compared to control
Downstream Regulation
Effect of modification (function):  acetylation
Comments:  acetylation of p53 sites

S20-p - p53 (human)
Modsite: PLsQEtFsDLWkLLP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S20‑p, p53 iso2 (human): S20‑p, p53 iso4 (human): , p53 (mouse): S23‑p, p53 iso2 (mouse): S23‑p, p53 (rat): S20‑p, p53 (rabbit): S20‑p, p53 (green monkey): S20‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol no change compared to control
nocodazole no change compared to control
Downstream Regulation
Effect of modification (function):  phosphorylation
Comments:  necessary for phosphorylation of other p53 sites

S33-p - p53 (human)
Modsite: LPENNVLsPLPsQAM SwissProt Entrez-Gene
Orthologous residues
p53 (human): S33‑p, p53 iso2 (human): S33‑p, p53 iso4 (human): , p53 (mouse): , p53 iso2 (mouse): , p53 (rat): P33‑p, p53 (rabbit): , p53 (green monkey): S33‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation no change compared to control
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase
Downstream Regulation
Effect of modification (function):  phosphorylation
Comments:  necessary for phosphorylation of other p53 sites

S37-p - p53 (human)
Modsite: NVLsPLPsQAMDDLM SwissProt Entrez-Gene
Orthologous residues
p53 (human): S37‑p, p53 iso2 (human): S37‑p, p53 iso4 (human): , p53 (mouse): , p53 iso2 (mouse): , p53 (rat): T37‑p, p53 (rabbit): S35‑p, p53 (green monkey): S37‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA no change compared to control
taxol no change compared to control
nocodazole no change compared to control

S46-p - p53 (human)
Modsite: AMDDLMLsPDDIEQW SwissProt Entrez-Gene
Orthologous residues
p53 (human): S46‑p, p53 iso2 (human): S46‑p, p53 iso4 (human): S7‑p, p53 (mouse): , p53 iso2 (mouse): , p53 (rat): , p53 (rabbit): S45‑p, p53 (green monkey): S46‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase

S315-p - p53 (human)
Modsite: LPNNtsssPQPkkkP SwissProt Entrez-Gene
Orthologous residues
p53 (human): S315‑p, p53 iso2 (human): S315‑p, p53 iso4 (human): S276‑p, p53 (mouse): S312‑p, p53 iso2 (mouse): S312‑p, p53 (rat): S313‑p, p53 (rabbit): S313‑p, p53 (green monkey): S315‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase

K320-ac - p53 (human)
Modsite: sssPQPkkkPLDGEy SwissProt Entrez-Gene
Orthologous residues
p53 (human): K320‑ac, p53 iso2 (human): K320‑ac, p53 iso4 (human): K281‑ac, p53 (mouse): K317‑ac, p53 iso2 (mouse): K317‑ac, p53 (rat): K318‑ac, p53 (rabbit): K318‑ac, p53 (green monkey): K320‑ac
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA no change compared to control
taxol no change compared to control
nocodazole no change compared to control

K382-ac - p53 (human)
Modsite: QstsRHkkLMFktEG SwissProt Entrez-Gene
Orthologous residues
p53 (human): K382‑ac, p53 iso2 (human): , p53 iso4 (human): K343‑ac, p53 (mouse): K379‑ac, p53 iso2 (mouse): , p53 (rat): K380‑ac, p53 (rabbit): K380‑ac, p53 (green monkey): K382‑ac
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA no change compared to control
taxol no change compared to control
nocodazole increase

S392-p - p53 (human)
Modsite: FktEGPDsD______ SwissProt Entrez-Gene
Orthologous residues
p53 (human): S392‑p, p53 iso2 (human): , p53 iso4 (human): S353‑p, p53 (mouse): S389‑p, p53 iso2 (mouse): , p53 (rat): S390‑p, p53 (rabbit): S390‑p, p53 (green monkey): S392‑p
Characterization
Methods used to characterize site in vivo modification-specific antibody, mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  colorectal cancer, colorectal carcinoma, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  A549 (pulmonary), HCT116 (intestinal), MEF (fibroblast), MRC5 (fibroblast), NCI-H1299 (pulmonary), WS1 (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing_radiation increase
UV increase
adriamycin increase
PALA increase
taxol increase
nocodazole increase